RT Journal Article
T1 Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept.
A1 González Astorga, B
A1 Salvà Ballabrera, F
A1 Aranda Aguilar, E
A1 Élez Fernández, E
A1 García-Alfonso, P
A1 González Flores, E
A1 Vera García, R
A1 Fernández Montes, A
A1 López Muñoz, A M
A1 Salud Salvia, A
K1 Aflibercept
K1 BRAF
K1 Colorectal cancer
K1 Metastatic
K1 Mutation
K1 Patient profile
K1 Patient selection
K1 RAS
K1 Treatment
AB Colorectal cancer is the second leading cause of cancer-related death worldwide. For metastatic colorectal cancer (mCRC) patients, it is recommended, as first-line treatment, chemotherapy (CT) based on doublet cytotoxic combinations of fluorouracil, leucovorin, and irinotecan (FOLFIRI) and fluorouracil, leucovorin, and oxaliplatin (FOLFOX). In addition to CT, biological (targeted agents) are indicated in the first-line treatment, unless contraindicated. In this context, most of mCRC patients are likely to progress and to change from first line to second line treatment when they develop resistance to first-line treatment options. It is in this second line setting where Aflibercept offers an alternative and effective therapeutic option, thought its specific mechanism of action for different patient's profile: RAS mutant, RAS wild-type (wt), BRAF mutant, potentially resectable and elderly patients. In this paper, a panel of experienced oncologists specialized in the management of mCRC experts have reviewed and selected scientific evidence focused on Aflibercept as an alternative treatment.
YR 2021
FD 2021-02-25
LK http://hdl.handle.net/10668/17231
UL http://hdl.handle.net/10668/17231
LA en
DS RISalud
RD Apr 8, 2025